

VIRGINIA BOARD OF PHARMACY

**PUBLIC HEARINGS FOR PROHIBITION ON INCLUSION OF VITAMIN E IN VAPING
PRODUCTS;
SCHEDULING OF CHEMICALS IN SCHEDULE I**

June 4, 2021
Virtual Meeting

Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233-1463

- CALL TO ORDER: The two public hearings were called to order at 9:10AM.
- PRESIDING: Kristopher Ratliff, Chairman
- MEMBERS PRESENT: Bernard Henderson
James L. Jenkins, Jr.
William Lee
Sarah Melton
Cheryl Nelson, Vice Chairman
Patricia Richards-Spruill
Dale St. Clair
- MEMBER ABSENT: Glenn Bolyard
- STAFF PRESENT: Caroline D. Juran, Executive Director
Annette Kelley, Deputy Executive Director
Ryan Logan, Deputy Executive Director
Beth O' Halloran, Deputy Executive Director
Ellen B. Shinaberry, Deputy Executive Director
Elaine Yeatts, Senior Policy Analyst, DHP
David E. Brown, D.C., Director, DHP
Barbara Allison-Bryan, M.D., Chief Deputy, DHP
James Rutkowski, Assistant Attorney General
Matt Treacy, Media Production Specialist
- CALL FOR PUBLIC COMMENT: Mr. Ratliff called for comment regarding the placement of the following chemicals into Schedule I:
- Compound expected to have hallucinogenic properties.
- 4-chloro-alpha-methylaminobutiophenone (other name: 4-chloro Buphedrone), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
- Cannabimimetic agents.
- ethyl-2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (other names: 5-fluoro-EMB-PINACA, 5F-AEB), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-enyl)indazole-3-carboxamide (other name: ADB-4en-PINACA), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

PUBLIC COMMENT:

Robyn Weimer, Chemistry Program Manager, Department of Forensic Science (DFS) stated that these chemicals were identified by DFS for the Board's consideration for possible inclusion in Schedule I pursuant to 54.1-3443 (D) of the Code of Virginia.

No other comments were offered.

COMMENT:

Mr. Ratliff called for comment regarding the proposed regulations for a prohibition on the sale by pharmaceutical processors of cannabis products to be used for vaping that contain Vitamin E acetate. The proposed action will replace emergency regulations currently in effect until February 25, 2022.

PUBLIC COMMENT:


There was no public comment offered.

ADJOURN:

The public hearings adjourned at 9:20AM.



Chairman



Caroline D. Juran, Executive Director

5-24-21

Date

9/24/2021

Date